Seattle Genetics (SGEN) Tops Q2 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- S&P 500 inches lower as Middle East tensions outweigh tech gains
- L3Harris CEO steps down amid conduct review, shares drop
- Reddit leads social media platforms in revenue growth per user
- Northland Upgrades Astera Labs (ALAB) to Outperform, 'Right Time, Customers, and Products'
- H.C. Wainwright Reiterates Buy Rating on Soluna (SLNH)
Seattle Genetics Reports Second Quarter 2017 Financial Results
July 27, 2017 4:02 PM EDT-Second Quarter 2017 Revenues Were $108.2 Million, Including $74.3 Million in ADCETRIS® (Brentuximab Vedotin) U.S. and Canada Net Sales-
-Positive Top-Line Data from ADCETRIS Phase 3 ECHELON-1 Trial; Full Data to be Submitted for Presentation at ASH Annual Meeting-
-Submission of Supplemental Biologics License Application for FDA Approval of ADCETRIS in Frontline Advanced Hodgkin Lymphoma Planned by End of 2017-
-ADCETRIS Supplemental Biologics License Application Submitted to FDA for Cutaneous T-Cell Lymphoma-
-Initiation of Pivotal Trial of Enfortumab Vedotin in Metastatic Urothelial... More
